Associations of UPF with all-cause mortality were attenuated by inflammatory markers and resting heart rate
THURSDAY, Feb. 12, 2026 (HealthDay News) — Higher consumption of ultraprocessed food (UPF) after cancer diagnosis is associated with increased rates of all-cause and cancer mortality, regardless of diet quality, according to a study published online Feb. 4 in Cancer Epidemiology, Biomarkers & Prevention.
Marialaura Bonaccio, Ph.D., from IRCCS Neuromed in Pozzilli, Italy, and colleagues longitudinally analyzed 802 men and women recruited in the Moli-sani Study with a previous cancer diagnosis to examine the relationship between postdiagnostic UPF consumption and mortality. Data on food intake were obtained at baseline and assessed at an average of 8.4 years after diagnosis. Overall diet quality was assessed using the Mediterranean Diet Score (MDS).
The researchers found that 281 deaths occurred during a median follow-up of 14.6 years. Multivariable (including MDS)-adjusted hazard ratios for higher UPF consumption (highest versus lowest tertiles) were 1.48 and 1.57 for all-cause and cancer mortality, respectively. The associations of UPF with all-cause mortality were attenuated by about 40 percent by inflammatory markers and resting heart rate levels taken together.
“The fact that the association between ultraprocessed foods and all-cause death persisted even after adjusting for overall diet quality suggests that the negative health effects are not explained solely by poor nutrient profiles, but that the level and nature of industrial food processing itself play an independent role in influencing long-term health outcomes,” Bonaccio said in a statement.
The enrollment phase of the Moli-sani study was partially supported by research grants from Pfizer Foundation.
Abstract/Full Text (subscription or payment may be required)
Aircrew Face Higher Odds of Radiation-Related Cancer Deaths
Preoperative Chemo + Immunotherapy Combo Shrinks Head, Neck Cancer Tumors
Couples" Coping Skills Help Reduce Depression in GI Cancer Survivors
Genomic Newborn Screening Could ID Cancer Predisposition Syndrome
Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings
Patient Education Increases Skin Cancer Screening in Stem Cell Transplant Survivors
Subclinical Cardiac Dysfunction Linked to Neurodegeneration in APOE-ε4 Carriers
Study IDs Gaps in Hereditary Breast Cancer Risk Assessment Before Gender-Affirming Mastectomy